The coexpression of the preS1 (1-42) and the core (1-144) antigen of HBV in E. coli.
OBJECTIVE
To study the therapeutic T cell vaccine for the treatment of chronic hepatitis B by improving the cellular immunization of HBsAg vaccine with the coexpression of the preS1 (1-42) and the Core (1-144) antigen of HBV in E. coli.


METHODS
The genes of HBcAg (1-144) and preS1 (1-42) were amplified and fused by PCR. This fused gene was inserted in the prokaryotic expression vector pET-11d and expressed in E. coli.


RESULTS
It was showed by SDS-PAGE that the protein molecular weight of the coexpression product was about 20 kD, 20% of all bacteria protein. The monoclonal antibodies against core and preS1 antibody could react with this fused protein by Western-blot technique respectively. The fused gene was verified by sequencing. Under the immune electron microscopy, this fused protein is typical particle of HBcAg but in an aggregated form.


CONCLUSIONS
The results might aid for studying T cell immunotherapeutic vaccine for chronic hepatitis B.
Zhao
Yangqing
Y
Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 100052.
Zhan
Meiyun
M
D017931:DNA Primers; D004926:Escherichia coli / Q000378:metabolism*; D015870:Gene Expression; D006512:Hepatitis B Core Antigens / Q000096:biosynthesis* / Q000235:genetics; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis* / Q000235:genetics; D008970:Molecular Weight; D016133:Polymerase Chain Reaction; D011498:Protein Precursors / Q000096:biosynthesis* / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics
D017931:DNA Primers; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; C050806:presurface protein 1, hepatitis B surface antigen